Glucokinase (Hexokinase-D or Hexokinase Type IV or EC 2.7.1.2) - Pipeline Review, H1 2016 - Global Markets Direct - Market Research

Glucokinase (Hexokinase-D or Hexokinase Type IV or EC 2.7.1.2) - Pipeline Review, H1 2016

Glucokinase (Hexokinase-D or Hexokinase Type IV or EC 2.7.1.2) - Pipeline Review, H1 2016 - Global Markets Direct - Market Research
Glucokinase (Hexokinase-D or Hexokinase Type IV or EC 2.7.1.2) - Pipeline Review, H1 2016
Published Jun 28, 2016
56 pages — Published Jun 28, 2016
Price US$ 3,500.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Glucokinase (Hexokinase-D or Hexokinase Type IV or EC 2.7.1.2) - Pipeline Review, H1 2016, provides in depth analysis on Glucokinase (Hexokinase-D or Hexokinase Type IV or EC 2.7.1.2) targeted pipeline therapeutics.

The report provides comprehensive information on the Glucokinase (Hexokinase-D or Hexokinase Type IV or EC 2.7.1.2), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Glucokinase (Hexokinase-D or Hexokinase Type IV or EC 2.7.1.2) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Glucokinase (Hexokinase-D or Hexokinase Type IV or EC 2.7.1.2)
- The report reviews Glucokinase (Hexokinase-D or Hexokinase Type IV or EC 2.7.1.2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Glucokinase (Hexokinase-D or Hexokinase Type IV or EC 2.7.1.2) targeted therapeutics and enlists all their major and minor projects
- The report assesses Glucokinase (Hexokinase-D or Hexokinase Type IV or EC 2.7.1.2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Glucokinase (Hexokinase-D or Hexokinase Type IV or EC 2.7.1.2) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Glucokinase (Hexokinase-D or Hexokin

  
Source:
Document ID
GMDHC0103TDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents24
  List of Tables51
  List of Figures51
Introduction61
  Global Markets Direct Report Coverage61
Glucokinase (Hexokinase-D or Hexokinase Type IV or EC 2.7.1.2) Overview71
Therapeutics Development83
  Glucokinase (Hexokinase-D or Hexokinase Type IV or EC 2.7.1.2) Products under Development by Stage of Development81
  Glucokinase (Hexokinase-D or Hexokinase Type IV or EC 2.7.1.2) Products under Development by Therapy Area91
  Glucokinase (Hexokinase-D or Hexokinase Type IV or EC 2.7.1.2) Products under Development by Indication101
Glucokinase (Hexokinase-D or Hexokinase Type IV or EC 2.7.1.2) Pipeline Products Glance112
  Late Stage Products111
  Early Stage Products121
Glucokinase (Hexokinase-D or Hexokinase Type IV or EC 2.7.1.2) Products under Development by Companies132
Glucokinase (Hexokinase-D or Hexokinase Type IV or EC 2.7.1.2) Therapeutics Assessment154
  Assessment by Monotherapy/Combination Products151
  Assessment by Mechanism of Action161
  Assessment by Route of Administration171
  Assessment by Molecule Type181
Glucokinase (Hexokinase-D or Hexokinase Type IV or EC 2.7.1.2) Companies Involved in Therapeutics Development1911
  Advinus Therapeutics Ltd191
  Amgen Inc.201
  Hua Medicine (Shanghai) Ltd.211
  LG Life Science LTD.221
  Ligand Pharmaceuticals, Inc.231
  Novartis AG241
  Poxel SA251
  Takeda Pharmaceutical Company Limited261
  Teijin Pharma Limited271
  vTv Therapeutics Inc281
  Yuhan Corporation291
Glucokinase (Hexokinase-D or Hexokinase Type IV or EC 2.7.1.2) Drug Profiles3013
  AM-9514 Drug Profile301
  GKM-001 Drug Profile311
  LC-280391 Drug Profile321
  LCZ-960 Drug Profile331
  Sinogliatin Drug Profile342
  Small Molecule to Activate Glucokinase for Type 2 Diabetes Drug Profile361
  Small Molecules to Activate Glucokinase for Type 2 Diabetes Drug Profile371
  Small Molecules to Activate Glucokinase for Type 2 Diabetes Drug Profile381
  TMG-123 Drug Profile391
  TTP-399 Drug Profile402
  YH-GKA Drug Profile421
Glucokinase (Hexokinase-D or Hexokinase Type IV or EC 2.7.1.2) Dormant Projects431
Glucokinase (Hexokinase-D or Hexokinase Type IV or EC 2.7.1.2) Discontinued Products441
Glucokinase (Hexokinase-D or Hexokinase Type IV or EC 2.7.1.2) Featured News &Press Releases4510
  Apr 12, 2016: vTv Therapeutics Announces Presentation of its Diabetes Product Candidate TTP399 at the Keystone Symposia on New Therapeutics for Diabetes and Obesity451
  Feb 09, 2016: vTv Therapeutics Completes Enrollment of Phase 2b Trial Evaluating TTP399 for the Treatment of Type 2 Diabetes451
  Aug 13, 2015: Hua Medicine's GKA Diabetes Drug Demonstrates High Efficacy in 4-Week Phase 1c Trial461
  Jun 04, 2015: vTv Therapeutics Initiates Patient Dosing in the AGATA Study, a six Month Phase 2 Study Evaluating TTP399, a Liver-selective GlucoKinase Activator, for the Treatment of Type 2 Diabetes461
  Mar 10, 2015: Hua Medicine Files IND in US for its Novel GKA-based Diabetes Drug471
  Feb 09, 2015: Hua Medicine Announces Positive Phase 1b Results in Diabetes with 4th-Generation Glucokinase Activator, Shows Robust 24-hour Glucose Control481
  Mar 26, 2014: Hua Medicine tests glucokinase activator in Chinese diabetics491
  Mar 19, 2014: Hua Medicine's Novel Glucokinase Activator Reports Positive Phase 1a Data Demonstrating Robust Glucose Regulatory Hormone Modulation &Commences Phase 1b Trials in Diabetes Patients502
  Aug 14, 2013: First Liver-Selective Glucokinase Activator for Type 2 Diabetes Demonstrates Normalized HbA1c and No Hypoglycemia in Clinical Trial521
  Nov 29, 2012: Hua Medicine's Glucokinase Activator Passes Provincial FDA Inspections, Phase I Trial Likely To Be Launched In 2013521
  Nov 23, 2012: Hua Medicine Advances Diabetic Drug Towards Trial521
  Nov 29, 2011: Advinus's Glucokinase Activator Achieves Early POC For Diabetes531
  Sep 07, 2010: GKM-001 Completes Phase I Single Ascending Dose Study532
Appendix552
  Methodology551
  Coverage551
  Secondary Research551
  Primary Research551
  Expert Panel Validation551
  Contact Us551
  Disclaimer561

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Glucokinase (Hexokinase-D or Hexokinase Type IV or EC 2.7.1.2) - Pipeline Review, H1 2016" Jun 28, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Glucokinase-Hexokinase-D-or-Hexokinase-Type-IV-or-EC-2-7-1-2-Pipeline-Review-H1-2016-2088-16028>
  
APA:
Global Markets Direct - Market Research. (2016). Glucokinase (Hexokinase-D or Hexokinase Type IV or EC 2.7.1.2) - Pipeline Review, H1 2016 Jun 28, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Glucokinase-Hexokinase-D-or-Hexokinase-Type-IV-or-EC-2-7-1-2-Pipeline-Review-H1-2016-2088-16028>
  
US$ 3,500.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.